TuisEVGN • NASDAQ
add
Evogene Ltd
Vorige sluiting
$0,84
Dagwisseling
$0,73 - $0,84
Jaarwisseling
$0,73 - $2,42
Markkapitalisasie
6,84 m USD
Gemiddelde volume
835,28 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 312,00 k | -82,63% |
Bedryfskoste | 2,88 m | -64,76% |
Netto inkomste | 3,87 m | 150,77% |
Netto winsgrens | 1,24 k | 392,27% |
Wins per aandeel | -0,46 | 64,51% |
EBITDA | -2,44 m | 64,22% |
Effektiewe belastingkoers | -0,04% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 15,96 m | -20,02% |
Totale bates | 26,09 m | -34,97% |
Totale aanspreeklikheid | 8,83 m | -68,31% |
Totale ekwiteit | 17,25 m | — |
Uitstaande aandele | 8,72 m | — |
Prys om te bespreek | 6,45 | — |
Opbrengs op bates | -22,70% | — |
Opbrengs op kapitaal | -39,13% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 3,87 m | 150,77% |
Kontant van bedrywe | -3,33 m | 32,37% |
Kontant van beleggings | 10,91 m | 441,12% |
Kontant van finansiering | -10,34 m | -318,34% |
Netto kontantverandering | -2,70 m | -247,46% |
Beskikbare kontantvloei | -385,62 k | -131,18% |
Meer oor
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
HUB
Gestig
1999
Webwerf
Werknemers
117